CompletedPhase 2NCT00301834

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Studying Diamond-Blackfan anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Francisco
Principal Investigator
Morton J. Cowan, MD
University of California, San Francisco
Intervention
alemtuzumab(biological)
Enrollment
35 enrolled
Eligibility
21 years · All sexes
Timeline
20052011

Study locations (2)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00301834 on ClinicalTrials.gov

Other trials for Diamond-Blackfan anemia

Additional recruiting or active studies for the same condition.

See all trials for Diamond-Blackfan anemia

← Back to all trials